HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $63 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Arcturus Therapeutics, maintaining a price target of $63.
October 01, 2024 | 4:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Arcturus Therapeutics, maintaining a price target of $63. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $63 price target by HC Wainwright & Co. indicates a positive outlook on Arcturus Therapeutics' stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100